Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

(2012) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

(2011) K Maeda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover

(2011) K. Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Effect of Cyclosporine on the Pharmacokinetics of Aliskiren in Healthy Subjects

(2011) Sam Rebello et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model

(2011) Helen E. Cubitt et al.   XENOBIOTICA

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype

(2010) Dinko Rekić et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions

(2010) E. J. Guest et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans

(2010) Motohiro Kato et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

(2009) A A Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

(2008) AA Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS